Vasonatrin Peptide (VNP) |cas:141676-35-9|西域试剂

Vasonatrin Peptide (VNP)

产品编号：西域质检-HY21556| CAS NO：141676-35-9| 分子式：C123H198N36O36S3| 分子量：2865.37

Vasonatrin Peptide (VNP) 是心钠素 (ANP) 和C型利钠肽 (CNP) 的嵌合体。Vasonatrin Peptide 具有 CNP 的静脉扩张作用、ANP 的利尿作用以及与 ANP 或 CNP 无关的独特的动脉血管扩张作用。Vasonatrin Peptide 通过 cGMP-PKG 信号通路抑制内质网应激对糖尿病心脏缺血再灌注损伤的保护作用。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
西域质检-HY21556	￥询价	杭州北京（现货）
西域质检-HY21556	￥询价	杭州北京（现货）
西域质检-HY21556	￥询价	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

产品名称

Vasonatrin Peptide (VNP)

CAS编号

141676-35-9

产品描述

溶解性数据

In Vitro:

H₂O

Peptide Solubility and Storage Guidelines:

1. Calculate the length of the peptide.

2. Calculate the overall charge of the entire peptide according to the following table:

	Contents	Assign value
Acidic amino acid	Asp (D), Glu (E), and the C-terminal -COOH.	-1
Basic amino acid	Arg (R), Lys (K), His (H), and the N-terminal -NH₂	+1
Neutral amino acid	Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q)	0

3. Recommended solution:

Overall charge of peptide	Details
Negative (<0)	1. Try to dissolve the peptide in water first. 2. If water fails, add NH₄OH (<50 μL). 3. If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (>0)	1. Try to dissolve the peptide in water first. 2. If water fails, try dissolving the peptide in a 10%-30% acetic acid solution. 3. If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0)	1. Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first. 2. For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.

体外研究

Vasonatrin Peptide (VNP) markedly enhances adiponectin mRNA expression, as well as protein secretion, however, suppresses IL-6 production in mature adipocytes. In addition, VNP significantly increases the intracellular levels of cGMP. The effects of VNP are mimicked by 8-br-cGMP, whereas inhibits by HS-142-1, or KT-5823。

体内研究

Vasonatrin peptide (100 μg/kg; i.v. ; 10 min before reperfusion) attenuates myocardial ischemia-reperfusion injury in diabetic rats.

XIYU has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	High-fat diet-fed streptozotocin-induced diabetic Sprague-Dawley rats
Dosage:	100 μg/kg
Administration:	I.v. ; 10 min before reperfusion
Result:	Significantly improved the instantaneous first derivation of left ventricle pressure (±LV dP/d_tmax) and LV systolic pressure and reduced LV end-diastolic pressure, apoptosis index, caspase-3 activity, plasma creatine kinase (CK), and lactate dehydrogenase (LDH) activities. Inhibited endoplasmic reticulum (ER) stress by suppressing glucose-regulated protein 78 (GRP78) and C/EBP homologous protein (CHOP).

储存条件

储存条件: -20°C

运输方式: 冰袋运输，根据产品的不同，可能会有相应调整。

化学品安全说明书(MSDS)

下载MSDS

Vasonatrin Peptide (VNP)

化学品安全说明书(MSDS)

质检证书(COA)

在线咨询